The article features an interview with Badal Shah, the Managing Director at Neolytica, a subsidiary of QPharma. Shah discusses how Neolytica is leveraging the power of health analytics, artificial intelligence (AI), and data science to address gaps in the biopharma industry.
The company aims to provide customized solutions for key opinion leader (KOL) identification and mapping, help medical and commercial teams collaborate, and improve medical education within biopharma companies. Shah highlights the increasing importance of KOLs in the post-pandemic era and explains how Neolytica’s platform measures customer success and differentiates itself from competitors. He also shares a success story and reveals future plans, including the launch of a new platform called TI Expert 2.0. The interview concludes with Shah discussing the motivation behind Neolytica’s work and sharing his personal journey with the company.
In the interview, Badal Shah, Managing Director at Neolytica, discusses the company’s mission, its unique approach to KOL identification and engagement, and its success in helping biopharma companies achieve their goals.
Shah highlights three major misconceptions that biopharma companies have about KOLs.
1. That KOLs can be identified based on their publications, trials, and conferences. In reality, biopharma companies need to identify rising stars and new KOLs who are active on client-specific key topics.
2. That KOLs who are highly active are more effective than KOLs with a solid network in the medical community. In reality, both types of KOLs are important, and biopharma companies need to identify the right mix of KOLs for their specific needs.
3. That Scientific Share of Voice (SSoV) is the best way to measure the impact of medical affairs. In reality, SSoV is a limited measure of impact, and biopharma companies need to use a more comprehensive approach that includes sentiment analysis.
Neolytica’s platform helps biopharma companies overcome these misconceptions and achieve their goals. The platform provides a comprehensive view of the KOL landscape, including KOL profiles, publications, and social media activity. It also provides tools for measuring the impact of medical affairs, including sentiment analysis.
Shah is confident that Neolytica has the potential to revolutionize the biopharma industry. He believes that the company’s platform can help biopharma companies improve patient outcomes, reduce costs, and accelerate drug development.
